We are live on ! Find out more
TGI

TRV GP IV Portfolio holdings

AUM $267M
1-Year Est. Return 965.83%
This Fund
S&P 500
This Quarter Est. Return
+72.76%
1 Year Est. Return
+965.83%
3 Year Est. Return
+686.22%
5 Year Est. Return
+581.56%
10 Year Est. Return
–
AUM
$160M
AUM Growth
+$62.7M
Cap. Flow
$0
Cap. Flow %
0%
Top 10 Hldgs %
100%
Holding
2
New
–
Increased
–
Reduced
–
Closed
–

Top Buys

No buys this quarter

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DNTH icon
1
Dianthus Therapeutics
DNTH
$5.84B
$121M 75.69%
500,513
– –
FULC icon
2
Fulcrum Therapeutics
FULC
$273M
$39M 24.31%
2,343,154
– –

Similar funds

OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
WAM
Weinberger Asset Management Los Angeles, California $267M AUM 19.83% 1-Year Est. Return
IP
Indigo Partners Phoenix, Arizona $267M AUM 9% 1-Year Est. Return
SIA
SGL Investment Advisors Missoula, Montana $266M AUM 18.29% 1-Year Est. Return
CFG
Cambridge Financial Group Columbus, Ohio $267M AUM 31.62% 1-Year Est. Return
EU
Emory University Atlanta, Georgia $267M AUM 48.26% 1-Year Est. Return
PC
Packer & Co Cottesloe, Australia $267M AUM
ALC
Alexander Labrunerie & Co Columbia, Missouri $267M AUM 21.24% 1-Year Est. Return

TRV GP IV's Q4 2019 Portfolio in Review

As of Q4 2019, TRV GP IV held 2 positions worth $160M, up 64% from $97.7M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q4 2019: portfolio turnover was 0%. TRV GP IV opened no new positions and made no exits, leaving the 2-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • TRV GP IV's ten largest holdings make up 100% of its $160M portfolio in Q4 2019.
  • TRV GP IV opened 0 new positions and closed 0 in Q4 2019.
  • TRV GP IV's portfolio value rose 64% quarter-over-quarter to $160M.

Based on TRV GP IV's 13F filing for Q4 2019, filed 5 Feb 2020.